BillionToOne's Northstar Response® Is a Stronger Predictor of Immunotherapy Outcomes Than Standard-of-Care Imaging for Cancer Patients in Peer-Reviewed Study
Rhea-AI Summary
BillionToOne (Nasdaq: BLLN) reported peer-reviewed data showing its Northstar Response tissue-free ctDNA assay was a stronger independent predictor of survival than standard-of-care imaging in 142 advanced solid tumor patients across 12 tumor types receiving immunotherapy.
Molecular progression via Northstar Response showed a hazard ratio of 5.3 for survival and identified progression a median of 62 days before clinicoradiographic imaging. Combining Northstar Response with imaging produced the highest predictive discrimination, with hazard ratios up to 19.7 when both modalities indicated progression.
Positive
- Molecular progression by Northstar Response showed survival hazard ratio of 5.3
- Combined Northstar Response plus imaging reached hazard ratios up to 19.7
- Northstar Response detected progression a median of 62 days before imaging
- Study included 142 patients across 12 solid tumor types
- Molecular monitoring added prognostic value in patients with radiographic stable disease
- Findings reproduced in an independent prospective validation cohort
Negative
- None.
News Market Reaction – BLLN
In the Jun 29 session, BLLN gained 1.89%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| May 27 | Conference participation | Positive | +7.5% | Management participation in William Blair growth conference drew investor interest. |
| May 06 | Earnings and guidance | Positive | +14.1% | Strong Q1 results with raised full-year revenue guidance boosted sentiment. |
| May 01 | Product launch | Positive | -6.9% | Launch of Unity Confirm prenatal diagnostic test met with negative price reaction. |
| Apr 15 | Earnings date notice | Neutral | -2.6% | Announcement of upcoming Q1 2026 results and conference call saw shares soften. |
| Apr 02 | Oncology leadership | Neutral | -4.3% | New oncology VP and CMO transition for Northstar portfolio accompanied by a pullback. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
BLLN has reacted strongly to major financial and oncology updates, with occasional selloffs following otherwise positive product or corporate news.
Key Terms
ctdna medical
recist medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
Tissue-free ctDNA monitoring was the dominant independent predictor of survival across 12 tumor types and two prospective cohorts
Conducted in collaboration with the Allegheny Health Network Cancer Institute, the study enrolled 142 patients across two independent cohorts spanning 12 solid tumor types. In a multivariate analysis incorporating both Northstar Response and blinded central radiographic review using RECIST criteria, molecular progression emerged as the dominant independent predictor of survival (hazard ratio 5.3), substantially outweighing radiographic progression. The strongest predictive performance came from pairing Northstar Response with imaging: patients whose disease progressed on both molecular and imaging assessment had the poorest outcomes of all (hazard ratio 13.8 at the landmark assessment; 19.7 with continued longitudinal monitoring), and the combined molecular-plus-imaging approach achieved the highest predictive discrimination of any method evaluated.
Northstar Response also helped resolve a particularly challenging clinical dilemma in oncology: patients whose imaging show "stable disease" and thus have findings that cannot reliably be distinguished between early treatment benefit and failure. Among these patients, molecular progression identified those at substantially higher risk and conveyed prognostic information that imaging alone could not provide.
On average, Northstar Response identified cancer progression a median of 62 days before clinicoradiographic progression, representing a potentially actionable window for oncologists to reassess surveillance or treatment strategy before conventional methods signal failure. The assay achieves this through simple serial blood draws collected throughout treatment that integrate into routine oncology practice.
"The lead time advantage here is reflective of real-world patient treatment situations and the rhythm of typical oncology practices — by using Response, a physician has information two treatment cycles earlier than they would when using imaging alone," said Ali Zaidi, MD, Professor of Surgery and Medicine at Drexel University College of Medicine; Medical Director of Aerodigestive Research at Allegheny Cancer Institute, Allegheny Health Network. "That window has real implications for how we manage patients."
The study also found that 1 in 4 patients exhibited a molecular rebound pattern (an early favorable decrease signal followed by a subsequent rise) that suggests a single ctDNA assessment could misclassify patients as responding when the likelihood of treatment failure remains high. Only through serial sampling across multiple cycles were the investigators able to fully capture this kinetic shift, underscoring an important limitation of single-timepoint monitoring approaches for patients receiving immunotherapy.
"For patients with advanced cancer on immunotherapy, the clinical question that matters most isn't whether treatment is working at week four — it's whether it's still working over time," said Dr. Zaidi. "These data show that serial molecular monitoring can answer that question earlier, and more independently, than imaging alone."
The Northstar Response assay uses proprietary single-molecule next-generation sequencing (smNGS) platform with Quantitative Counting Template™ (QCT™) technology to quantify tumor-specific methylation from a simple blood draw, enabling treatment response monitoring across multiple solid tumor types. Northstar Response complements Northstar Select®, BillionToOne's liquid biopsy for therapy selection in cancer patients. Together, the assays support clinicians from treatment selection through ongoing response monitoring without dependence on tumor tissue.
"Therapy selection and treatment monitoring are two of the most important decisions in oncology," said Allen Chen, MD, Vice President of Oncology Clinical Development and Medical Affairs at BillionToOne. "Through simple blood draws, Northstar Select and Northstar Response provide clinicians with complementary molecular tools that allow for truly personalized cancer care to guide patients throughout their treatment journey."
About BillionToOne
Headquartered in
About Northstar Select®
Northstar Select, BillionToOne's highly sensitive comprehensive genomic profiling (CGP) liquid biopsy assay, demonstrated superior performance in detecting more clinically actionable alterations in circulating tumor DNA (ctDNA) compared to other liquid biopsy tests on the market. In a prospective head-to-head comparison study which included 182 patients with more than 17 solid tumor types, Northstar Select detected
About Northstar Response®
Northstar Response is BillionToOne's tissue-free, methylation-based ctDNA assay purpose-built for treatment response monitoring in patients with cancer. Powered by the company's patented QCT™ molecular counting platform — the only multiplex technology capable of counting DNA molecules at the single-molecule level — Northstar Response quantifies tumor burden through serial blood draws with no dependence on tumor tissue at any stage of the patient journey.
Disclaimer
Northstar Select and Northstar Response may produce false-positive or false-negative results. Test results are not a guarantee of the presence or absence of disease or treatment response and should not be used as the sole basis for medical decision-making. Results should be interpreted in conjunction with the patient's clinical presentation, radiographic findings, and other diagnostic information. Northstar Response is intended to complement, not replace, standard clinical and radiographic assessment of disease status. Northstar Select and Northstar Response are laboratory-developed tests (LDTs) performed in a CLIA-certified and CAP-accredited laboratory. These tests have not been cleared or approved by the U.S. Food and Drug Administration (FDA). Test performance may vary based on factors including cancer type, disease burden, treatment, and specimen characteristics.
Forward-Looking Statements
This press release contains certain forward-looking statements within the meaning of federal securities laws. These forward-looking statements generally are identified by the words "believe," "project," "expect," "anticipate," "estimate," "intend," "strategy," "future," "opportunity," "plan," "may," "should," "will," "would," "will be," "will continue," "will likely result," and similar expressions. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Forward-looking statements in this press release include, but are not limited to, statements regarding the clinical performance and utility of Northstar Response. These statements are based on management's current expectations, forecasts and assumptions, and actual outcomes and results could differ materially from these statements due to a number of factors, some of which are beyond BillionToOne's control. These and additional risks and uncertainties could affect BillionToOne's financial and operating results and cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. These risks and uncertainties include, but are not limited to, those discussed under the captions "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operation" and elsewhere in BillionToOne's most recently filed Quarterly Report on Form 10-Q, its Annual Report on Form 10-K, and other filings the company makes with the Securities and Exchange Commission from time to time. The forward-looking statements in this press release are based on information available to BillionToOne as of the date hereof, and BillionToOne disclaims any obligation to update any forward-looking statements provided to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based, except as required by law. These forward-looking statements should not be relied upon as representing BillionToOne's views as of any date subsequent to the date of this press release.
1. Anees et al. Longitudinal Methylated ctDNA Increases Predict Immunotherapy Progression Across Solid Tumors, The Journal of Liquid Biopsy, https://doi.org/10.1016/ j.jlb.2026.100477
2. Bower, X., Wignall, J., Varga, M. G., et al. Validation of a liquid biopsy assay with increased sensitivity for clinical comprehensive genomic profiling. The Journal of Liquid Biopsy. https://doi.org/10.1016/j.jlb.2025.100322. Head-to-head improvement % determined when compared to comparator products in the aggregate. Actual percentages may vary depending on the individual comparator liquid biopsy test.
Media Contact
billiontoone@moxiegrouppr.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/billiontoones-northstar-response-is-a-stronger-predictor-of-immunotherapy-outcomes-than-standard-of-care-imaging-for-cancer-patients-in-peer-reviewed-study-302813448.html
SOURCE BillionToOne